Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) have received a consensus rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $97.23.

A number of equities research analysts recently issued reports on the stock. Piper Sandler upgraded shares of Intra-Cellular Therapies from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $68.00 to $92.00 in a research report on Friday, September 6th. Cantor Fitzgerald restated an “overweight” rating and issued a $130.00 price objective on shares of Intra-Cellular Therapies in a research report on Monday, September 16th. Morgan Stanley raised their price objective on shares of Intra-Cellular Therapies from $92.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Needham & Company LLC restated a “buy” rating and issued a $100.00 price objective on shares of Intra-Cellular Therapies in a research report on Wednesday, October 30th. Finally, Royal Bank of Canada raised their price objective on shares of Intra-Cellular Therapies from $106.00 to $108.00 and gave the company an “outperform” rating in a research report on Friday, October 4th.

Intra-Cellular Therapies Price Performance

Shares of Intra-Cellular Therapies stock opened at $86.17 on Thursday. Intra-Cellular Therapies has a fifty-two week low of $52.88 and a fifty-two week high of $88.00. The firm has a fifty day moving average price of $75.41 and a two-hundred day moving average price of $73.31.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its quarterly earnings data on Wednesday, October 30th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.07). Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. The business had revenue of $175.40 million during the quarter, compared to analyst estimates of $172.30 million. During the same quarter in the prior year, the company posted ($0.25) EPS. The company’s quarterly revenue was up 39.0% compared to the same quarter last year. As a group, analysts expect that Intra-Cellular Therapies will post -0.61 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Sharon Mates sold 53,013 shares of the company’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $75.65, for a total transaction of $4,010,433.45. Following the completion of the sale, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $80,970,388.85. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, CEO Sharon Mates sold 53,013 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The stock was sold at an average price of $75.65, for a total value of $4,010,433.45. Following the completion of the transaction, the chief executive officer now owns 1,070,329 shares of the company’s stock, valued at $80,970,388.85. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Mark Neumann sold 18,714 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $75.08, for a total transaction of $1,405,047.12. Following the sale, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at $2,229,876. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 175,316 shares of company stock valued at $13,037,345 over the last quarter. 2.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Intra-Cellular Therapies

A number of institutional investors and hedge funds have recently modified their holdings of the business. Headlands Technologies LLC bought a new position in shares of Intra-Cellular Therapies in the 1st quarter worth $32,000. Fidelis Capital Partners LLC bought a new stake in shares of Intra-Cellular Therapies during the 1st quarter worth $53,000. Summit Securities Group LLC bought a new stake in Intra-Cellular Therapies in the 2nd quarter valued at about $56,000. Capital Performance Advisors LLP bought a new stake in Intra-Cellular Therapies in the 3rd quarter valued at about $74,000. Finally, CWM LLC grew its holdings in Intra-Cellular Therapies by 83.9% during the 2nd quarter. CWM LLC now owns 1,372 shares of the biopharmaceutical company’s stock valued at $94,000 after buying an additional 626 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.